"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 0 | 3 |
| 2010 | 7 | 0 | 7 |
| 2011 | 2 | 1 | 3 |
| 2012 | 11 | 1 | 12 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 4 | 1 | 5 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 3 | 4 |
| 2020 | 6 | 0 | 6 |
| 2021 | 10 | 1 | 11 |
| 2022 | 5 | 0 | 5 |
| 2023 | 5 | 0 | 5 |
| 2024 | 7 | 2 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Kohan L, Barreveld A, Potru S, Abd-Elsayed A, Viscusi ER. Narrative review: Managing buprenorphine and opioid use disorder in the perioperative setting. Pain Pract. 2025 Jan; 25(1):e13427.
-
Reed MK, Camacho TE, Gillingham J, Gill S, Gannon M, Abatemarco D, Kelly EL, Weinstein LC. Patient and navigator experiences with the opioid use disorder treatment system in Philadelphia, PA. J Subst Use Addict Treat. 2024 Dec; 167:209509.
-
Roth E, Bingaman A, Stern S, McKeever R, D'Orazio J, Schlosser SP, Cheng K, Zhao H, Anderson JH. Buprenorphine Induction in Trauma Patients With Opioid Use Disorder - A Single Center Experience? J Surg Res. 2024 Sep; 301:686-695.
-
Anbalagan S, Anderson V, Favara MT, Stark D, Carola D, Solarin K, Adeniyi-Jones S, Kraft WK, Aghai ZH. Buprenorphine vs. morphine: impact on neonatal opioid withdrawal syndrome (NOWS) outcomes in a single center retrospective study. J Perinatol. 2025 Apr; 45(4):473-479.
-
Petrakis IL, Meshberg-Cohen S, Nich C, Kelly MM, Claudio T, Jane JS, Pisani E, Ralevski E. Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine. Am J Addict. 2024 Sep; 33(5):525-533.
-
Santos T, Bergman A, Smith-McLallen A. Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus. JAMA Netw Open. 2024 04 01; 7(4):e248519.
-
Mallinson DC, Kuo HD, Kirby RS, Wang Y, Berger LM, Ehrenthal DB. Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018. Prev Med. 2024 Apr; 181:107914.
-
Maisel BA, Adeniyi-Jones SC, Selvage E, Ng S, Kraft WK, Chervoneva I. Abstinence scoring algorithms for treatment of neonatal opioid withdrawal syndrome (NOWS). J Perinatol. 2024 Aug; 44(8):1132-1136.
-
Hagan L, David EM, Horton AR, Marx JO. Effects of Midazolam/Dexmedetomidine with Buprenorphine or Extended-release Buprenorphine Anesthesia in C57BL/6 Mice. J Am Assoc Lab Anim Sci. 2024 03 01; 63(2):172-181.
-
Gannon M, Hand D, Short V, McLaughlin K, Flood T, Shaffer K, Lenegan N, Abatemarco D, DiDonato S. Maternal Perspective of Inpatient Methadone Initiation: Opportunities to Increase Retention in Treatment. J Addict Med. 2024 Mar-Apr 01; 18(2):122-128.